New York, NY (PRWEB) January 11, 2016
Schrödinger, Inc. announced today that it has entered into a research collaboration agreement with Pfizer Inc. (NYSE: PFE), in which the two companies will work together to develop a computational model for predicting key properties relevant to biotherapeutic candidates.
In this collaboration, each company will perform tasks in an attempt to develop a novel model for predictions of properties. Pfizer will generate and provide experimental data against which the computational model is to be developed by the Schrödinger team, while teams from both companies will work together to determine future systems of interest to which to apply, test, and further refine the developing technology.
“Schrödinger has made key scientific breakthroughs in recent years in the areas of protein and ligand structure determination and potency prediction that have made a significant impact on drug discovery,” said Dr. Ramy Farid, Schrödinger’s President and Board Member. “We are thrilled to work together on developing technology that could potentially be applied to pharmaceutical research.”